Business Wire

CA-DATAPLOR

18.4.2024 15:01:35 CEST | Business Wire | Press release

Share
dataplor Announces Series A Funding Led by Spark Capital to Expand Global Location Data Intelligence

dataplor, the leading provider of global location intelligence, today announced a $10.6 million Series A funding round led by Spark Capital. This round, which included participation from Quest Venture Partners, Acronym Venture Capital, Circadian Ventures, Two Lanterns Venture Partners and APA Venture Partners, will further accelerate dataplor’s ongoing expansion, building the most accurate, comprehensive and dynamically updated database of global Point of Interest (POI) data on the market.

Today, dataplor offers data coverage across more than 200 countries and territories, encompassing over 300 million locations and over 15,000 brands. Companies in industries including technology, mapping, search, third party logistics, consumer packaged goods (CPG), telecom, investing, real estate and finance rely on dataplor’s global, accurate coverage to power strategic decisions and investments. With this latest funding, dataplor is positioned to expand its worldwide coverage and continue building out its team.

“Our mission at dataplor has always been about unlocking the true potential of POI data, making it accessible and actionable at a global scale,” said Geoff Michener, CEO and founder of dataplor. “This funding validates our vision and market-leading product and empowers us to accelerate our efforts, driving growth while aligned to our core values of accuracy, quality and privacy.”

dataplor’s proprietary approach merges technologies including artificial intelligence, machine learning, LLMs, and a purpose built technology platform with a global team of expert human validators. This combination allows the company to gather accurate, deduplicated and verified location data while providing a framework for regular updates to the information to stay current.

“dataplor solves a critical gap for companies seeking to scale in international markets: accurate, actionable data that unlocks business opportunities,” said Alex Finkelstein, General Partner at Spark Capital. “We see a massive potential market opportunity ahead for dataplor, but we’ve also been impressed by their traction, winning dozens of Fortune 500 customers and growing revenue by an average of 2.5x year-over-year since 2020. We’re very confident in this company’s bright future.”

Finkelstein will join dataplor’s board of directors, which includes John Frankel, founding partner of ffVC.

In addition to receiving accurate, updated and global POI data coverage, dataplor’s customers also benefit from the company’s commitment to privacy. All of the information in dataplor’s datasets is gathered through direct contact with a business or through publicly available data; no personally identifiable information (PII) is used. This approach not only aligns with the company’s ethical commitments but also ensures dataplor’s customers won’t be burdened with any regulatory or legal repercussions.

About dataplor

dataplor is a leading geospatial data company that helps global enterprises grow abroad by mapping tough-to-reach markets with a privacy-first approach. As the majority of international location data is inaccurate and quickly out of date, dataplor goes several steps further than the industry standard to help the world’s largest companies in technology, mapping, search, third party logistics, consumer packaged goods (CPG), telecom, investing, real estate and finance understand intelligence about any commercial or physical location in the world, in real-time, to fuel expansion abroad.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418167357/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release

Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye